About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: BMRN
- CUSIP: 09061G10
- Previous Close: $90.24
- 50 Day Moving Average: $87.94
- 200 Day Moving Average: $89.13
- 52-Week Range: $72.96 - $102.49
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -80.89
- P/E Growth: -0.96
- Market Cap: $15.44B
- Outstanding Shares: 171,987,000
- Beta: 1.58
- Net Margins: -46.22%
- Return on Equity: -8.54%
- Return on Assets: -5.51%
Companies Related to BioMarin Pharmaceutical:
- Debt-to-Equity Ratio: 0.25%
- Current Ratio: 4.42%
- Quick Ratio: 3.50%
What is BioMarin Pharmaceutical's stock symbol?
BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."
Where is BioMarin Pharmaceutical's stock going? Where will BioMarin Pharmaceutical's stock price be in 2017?
19 brokerages have issued 12 month price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $84.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $113.95 in the next twelve months.
When will BioMarin Pharmaceutical announce their earnings?
BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about BioMarin Pharmaceutical stock?
Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
According to Zacks Investment Research, "BioMarin should continue to see growth in both its orphan disease drugs – Vimizim and Kuvan – in 2017. Robust patient growth and penetration should propel the drugs’ sales. The company’s progress with its pipeline has been impressive. Moreover, loss estimates have narrowed lately ahead of the company's Q4 results. Its stock has outperformed the Zacks classified Medical-Biomedical and Genetics industry in the past one year. However, BioMarin has suffered quite a few regulatory setbacks related to its pipeline candidates, Brineura and Kyndrisa. Delayed approvals or development setbacks could have a negative impact on the stock. Also, the company’s top line is under pressure due to political and macroeconomic instability in Brazil and the Middle East. Meanwhile, BioMarin is facing generic threat for key drug Kuvan. The earlier-than-expected entry of generics would be a huge blow for the company." (2/1/2017)
Cowen and Company analysts commented, "We believe 2H16 conservatism leaves shares poised to move higher. We look favorably on TMO’s Q2 result and updated 2016 outlook, which includes a faster rate of organic revenue growth (+~4.5% vs. prior ~+4%) and operating margin expansion at the high end of previous guidance (+60-70 bps y/y vs. prior +50-70 bps). We continue to believe that TMO’s diversification and broad-based growth will insulate the co.’s performance, and like mgmt’s conservative strategy of leaving a recovery in industrials (~10% of sales/~50% of industrial/ applied sales) and stability in foreign exchange rates as upside. China and the Pharma/Biotech end-market continue to lead growth, rising mid-teens on a mid-teens comp and high-single digits on a mid-teens comp, respectively. In China, softness in pure industrial has been more than offset by strength in applied (with an emphasis on environmental protection and food safety), healthcare, and life sciences (the convergence of tools, diagnostics, and precision medicine). While bioproduction was cited as the strongest of TMO’s Pharma/Biotech businesses in the quarter, growth in this end market remains solid across customer type, geography, and utility (e.g. production vs. research and discovery)." (7/28/2016)
Who owns BioMarin Pharmaceutical stock?
BioMarin Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Sands Capital Management LLC (5.45%), State Street Corp (2.18%), Temasek Holdings Private Ltd (2.02%), Palo Alto Investors LLC (1.14%), Viking Global Investors LP (0.81%) and William Blair Investment Management LLC (0.64%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis.
Who sold BioMarin Pharmaceutical stock? Who is selling BioMarin Pharmaceutical stock?
BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Fred Alger Management Inc., William Blair Investment Management LLC, TCW Group Inc., FIL Ltd, Ithaka Group LLC, GLG LLC and GSA Capital Partners LLP. Company insiders that have sold BioMarin Pharmaceutical stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis.
Who bought BioMarin Pharmaceutical stock? Who is buying BioMarin Pharmaceutical stock?
BioMarin Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Marshall Wace LLP, AMF Pensionsforsakring AB, Asset Management One Co. Ltd., Palo Alto Investors LLC, State Street Corp, Frontier Capital Management Co. LLC and Alyeska Investment Group L.P..
How do I buy BioMarin Pharmaceutical stock?
Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of BioMarin Pharmaceutical stock cost?
One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $89.79.